Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for extravagance SUVs for seniors05.06.2024 - 2Building a Maintainable Closet: Individual Excursions in Moral Style25.09.2023
- 3The Craft of Computerized Detox: Individual Trials22.09.2023
- 4Instructions to Keep up with Your Traded Teeth for Life span16.10.2023
- 5The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with05.06.2024
- 5 things for parents to know about changes to kids vaccine schedule
- 75% of US adults may meet criteria for obesity under new definition, study finds
- Instructions to Pick the Right Tires for Your Slam 1500.
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- 7 Delightful Ferris Wheels, Do You Like Them?
- The Excursion to Monetary Proficiency: Individual budget Triumphs
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
